Convergence Pharmaceuticals and Selcia in r&d collaboration

Convergence Pharmaceuticals has entered into a drug discovery collaboration with Selcia to identify and develop high quality candidate molecules for the treatment of chronic pain.

Convergence Pharmaceuticals, a new company focused on the development of novel and high value analgesic medicines, has entered into a drug discovery collaboration with contract research organisation Selcia to identify and develop high quality candidate molecules for the treatment of chronic pain.

Under the terms of the agreement, Convergence will apply its ion channel biology platform, medicinal chemistry know-how and preclinical development expertise to Selcia’s medicinal chemistry and chemistry support services. Financial terms were not disclosed.

Convergence Pharmaceuticals is an independent biotechnology company formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline. The company, led by ceo Clive Dix, has a pipeline of differentiated clinical-stage compounds targeting the points of convergence in chronic pain signalling through modulation of specific ion-channels.

‘Following the successful l